Skip NavigationSkip to Content
Return Return to Search Results

Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies

  1. Author:
    Quang, Chau
    Chung, Amy W
    Kemp,Troy
    Ratu, Tupou
    Tuivaga, Evelyn
    Russell, Fiona M
    Licciardi, Paul V
    Toh, Zheng Q [ORCID]

  2. Author Address

    Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia., Vaccine Immunology, Murdoch Children 39;s Research Institute, Parkville, VIC, Australia., Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia., HPV Serology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA., Ministry of Health and Medical Services, Suva, Fiji.,
    1. Year: 2024
    2. Date: Jun
  2. Journal: Journal of Medical Virology
    1. 96
    2. 6
    3. Pages: e29732
  4. Type of Article: Article
  5. Article Number: e29732
  1. Abstract:

    Neutralizing antibodies (NAbs) are considered the primary mechanism of vaccine-mediated protection against human papillomaviruses (HPV), the causative agent of cervical cancer. However, the minimum level of NAb needed for protection is currently unknown. The HPV pseudovirion-based neutralization assay (PBNA) is the gold standard method for assessing HPV antibody responses but is time-consuming and labor-intensive. With the development of higher valency HPV vaccines, alternative serological assays with the capacity for multiplexing would improve efficiency and output. Here we describe a multiplex bead-based immunoassay to characterize the antibody responses to the seven oncogenic HPV types (HPV16/18/31/33/45/52/58) contained in the current licensed nonavalent HPV vaccine. This assay can measure antibody isotypes and subclasses (total IgG, IgM, IgA1-2, IgG1-4), and can be adapted to measure other antibody features (e.g., Fc receptors) that contribute to vaccine immunity. When tested with serum samples from unvaccinated and vaccinated individuals, we found high concordance between HPV-specific IgG using this multiplex assay and NAbs measured with PBNA. Overall, this assay is high-throughput, sample-sparing, and time-saving, providing an alternative to existing assays for the measurement and characterization of HPV antibody responses. © 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1002/jmv.29732
  3. PMID: 38874202

Library Notes

  1. Fiscal Year: FY2023-2024
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel